Sergey A. Lyakhov

Sergey A. Lyakhov

Auto-generated profile, based on publicly available information

Sergey A. Lyakhov

National Academy of Sciences of Ukraine

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMarina O. Shibinskaya
Marina O. Shibinskaya
SLSergey A. Lyakhov
Sergey A. Lyakhov
AMAlexander V. Mazepa
Alexander V. Mazepa
SASergey A. Andronati
Sergey A. Andronati
ATAlexander V. Turov
Alexander V. Turov
NSNikolay Ya. Spivak
Nikolay Ya. Spivak

1 June 2015 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
ISIgor A. Schepetkin
Igor A. Schepetkin
LKLiliya N. Kirpotina
Liliya N. Kirpotina
DHDeepa Hammaker
Deepa Hammaker
IKIrina Kochetkova
Irina Kochetkova
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
Mark QuinnMark Quinn
Mark Quinn
C-Jun N-terminal kinases (JNKs) participate in many physiologic and pathologic processes, including inflammatory diseases. We recently synthesized the sodium salt of IQ-1S (11H-indeno[1,2-b]quinoxalin-11-one oxime) and demonstrated that it is a high-affinity JNK inhibitor and inhibits murine delayed-type hypersensitivity. Here we show that IQ-1S is highly specific for JNK and that its neutral form is the most abundant species at physiologic pH. Molecular docking of the IQ-1S syn isomer into the JNK1 binding site gave the best pose, which corresponded to the position of cocrystallized JNK inhibitor SP600125 (1,9-pyrazoloanthrone). Evaluation of the therapeutic potential of IQ-1S showed that it inhibited matrix metalloproteinase 1 and 3 gene expression induced by interleukin-1β in human fibroblast-like synoviocytes and significantly attenuated development of murine collagen-induced arthritis (CIA). Treatment with IQ-1S either before or after induction of CIA resulted in decreased clinical scores, and joint sections from IQ-1S–treated CIA mice exhibited only mild signs of inflammation and minimal cartilage loss compared with those from control mice. Collagen II–specific antibody responses were also reduced by IQ-1S treatment. By contrast, the inactive ketone derivative 11H-indeno[1,2-b]quinoxalin-11-one had no effect on CIA clinical scores or collagen II–specific antibody titers. IQ-1S treatment also suppressed proinflammatory cytokine and chemokine levels in joints and lymph node cells. Finally, treatment with IQ-1S increased the number of Foxp3+CD4+CD25+ regulatory T cells in lymph nodes. Thus, IQ-1S can reduce inflammation and cartilage loss associated with CIA and can serve as a small-molecule modulator for mechanistic studies of JNK function in rheumatoid arthritis.

31 August 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ELElena A. Lyakhova
Elena A. Lyakhova
YGYulia A. Gusyeva
Yulia A. Gusyeva
JNJulia V. Nekhoroshkova
Julia V. Nekhoroshkova
LSLev M. Shafran
Lev M. Shafran
SLSergey A. Lyakhov
Sergey A. Lyakhov

20 September 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SLSerhii A. Liakhov
Serhii A. Liakhov
ISIgor Schepetkin
Igor Schepetkin
OKOlexander Karpenko
Olexander Karpenko
HDHanna I. Duma
Hanna I. Duma
NHNadiia M. Haidarzhy
Nadiia M. Haidarzhy
Mark QuinnMark Quinn
Mark Quinn
C-Jun N-terminal kinase (JNK) plays a central role in stress signaling pathways implicated in important pathological processes, including rheumatoid arthritis and ischemia-reperfusion injury. Therefore, inhibition of JNK is of interest for molecular targeted therapy to treat various diseases. We synthesized 13 derivatives of our reported JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime and evaluated their binding to the three JNK isoforms and their biological effects. Eight compounds exhibited submicromolar binding affinity for at least one JNK isoform. Most of these compounds also inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) activation and interleukin-6 (IL-6) production in human monocytic THP1-Blue cells and human MonoMac-6 cells, respectively. Selected compounds (4f and 4m) also inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. We conclude that indenoquinoxaline-based oximes can serve as specific small-molecule modulators for mechanistic studies of JNKs, as well as potential leads for the development of anti-inflammatory drugs.

1 November 2006 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
AKA. S. Karpenko
A. S. Karpenko
MSM. O. Shibinskaya
M. O. Shibinskaya
Nadiia М ZholobakNadiia М Zholobak
Nadiia М Zholobak
ZOZ. M. Olevinskaya
Z. M. Olevinskaya
SLS. A. Lyakhov
S. A. Lyakhov
SAS. A. Andronati
S. A. Andronati

1 August 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KKKyrylo Klimenko
Kyrylo Klimenko
SLSergey Lyakhov
Sergey Lyakhov
MSMarina Shibinskaya
Marina Shibinskaya
AKAlexander Karpenko
Alexander Karpenko
GMGilles Marcou
Gilles Marcou
Alexandre VarnekAlexandre Varnek
Alexandre Varnek